OpenNashPodcasts

Person

Ran Balicer

Ran Balicer is an Israeli public health leader whose appearance on the NEJM AI Grand Rounds podcast covered how Clalit, one of Israel's four health funds, uses data and artificial intelligence. He spoke about pandemic preparation, COVID-19 vaccine research, and screening for hepatitis C.

Balicer said Clalit's studies produced the first accurate real-world estimate of COVID-19 vaccine effectiveness by February 2021. He said a Clalit programme cut hospital admissions among patients with several chronic conditions by 43%. He also said a machine learning model found 38 additional hepatitis C patients by screening fewer than 500 people. He was appointed chair of Israel's national advisory team on pandemic response in 2020.

1 episodes · 18 quoted claims

The 1997 Hong Kong avian influenza outbreak, according to Ran Balicer, sickened 18 people and killed about one third of them.

“It was an event in which 18 people got sick with avian flu, and one third of them actually died from the virus.”

NEJM AI Grand Rounds · 0:07:42

After Ran Balicer presented his cost analysis to the Israeli cabinet, the government decided within about ten minutes to buy roughly $100 million of antiviral drugs for a possible flu pandemic.

“10 minutes later, they make a decision to buy drugs in $100 million.”

NEJM AI Grand Rounds · 0:09:14

Israel passed the National Health Insurance Law in 1994.

“Israel had a landmark piece of legislation put forward in 1994, the National Health Insurance Law.”

NEJM AI Grand Rounds · 0:20:08

According to Ran Balicer, the 1994 law made Israel's four health funds responsible for all their members' medical needs, paid nationally through capitation.

“make the four health funds to become responsible end-to-end for the life of their patients and for all their medical needs throughout their life and paid nationally through capitation.”

NEJM AI Grand Rounds · 0:20:08

By about 2010, Clalit had roughly 15 years of linked longitudinal records covering primary, specialty and hospital care plus claims and provider data.

“we already had like 15 years of longitudinal data, end-to-end, primary care, specialty care, hospital care, claims, and provider data.”

NEJM AI Grand Rounds · 0:20:35

Ran Balicer says the Clalit Research Institute grew from four people to 70 within a few years of the mid-2010s.

“Because in a few years, we grew from four people to 70.”

NEJM AI Grand Rounds · 0:21:58

Ran Balicer says a Clalit program targeting its lowest-performing, less affluent clinics cut some key health-quality gaps by 60% within three years.

“within three years of an intervention, large scale, we were able to show a 60 % reduction in some of the key measures.”

NEJM AI Grand Rounds · 0:22:28

Ran Balicer says another Clalit program reduced hospital admission rates among patients with multiple chronic conditions by 43%.

“On another program, we were able to reduce, for instance, admission rates on multimorbid patients by 43%.”

NEJM AI Grand Rounds · 0:23:18

The Clalit team led by Noa Dagan won first place in the New England Journal of Medicine's SPRINT data challenge in 2017.

“I couldn't have been more proud when the New England Journal of Medicine chose our solution as their first place winner.”

NEJM AI Grand Rounds · 0:24:33

Ran Balicer says Israel vaccinated about 2 million people in roughly three weeks early in its COVID-19 vaccination campaign.

“You know, 2 million people in about three weeks.”

NEJM AI Grand Rounds · 0:37:03

Clalit's COVID-19 vaccine studies matched each vaccinated person to an otherwise identical unvaccinated person and followed the pairs, emulating a randomized trial.

“Every vaccinee got somebody who was absolutely identical to them, except that they weren't vaccinated at the time, and we followed them like it was a trial.”

NEJM AI Grand Rounds · 0:38:28

Ran Balicer says Clalit produced the first accurate estimate of real-world COVID-19 vaccine effectiveness by February 2021 and published it in the New England Journal of Medicine.

“we had by February 2021, the world's first very accurate estimate of vaccine effectiveness.”

NEJM AI Grand Rounds · 0:38:28

Ran Balicer was appointed chair of the Israeli government's national advisory team on pandemic response during COVID-19.

“I was appointed as the government's chair of the national advisory team on pandemic response for Israel.”

NEJM AI Grand Rounds · 0:39:04

Ran Balicer says about one in three people with chronic hepatitis C eventually develop cirrhosis after decades of silently carrying the virus.

“in a few decades of silently carrying the virus, one in three will end up with cirrhosis”

NEJM AI Grand Rounds · 0:46:50

Ran Balicer says modern hepatitis C treatment was 98.8% effective in one of Clalit's own earlier studies.

“Okay. It's 98.8 effective. That's according to one of our own past studies.”

NEJM AI Grand Rounds · 0:46:50

Ran Balicer says routine screening is inadequate for the World Health Organization's goal of eliminating hepatitis C by 2030.

“But it's completely inadequate if we want to reach elimination of this disease by 2030 as the WHO set as a goal.”

NEJM AI Grand Rounds · 0:47:18

In Clalit's prospective study, screening fewer than 500 people ranked highest-risk by a machine learning model found 38 additional hepatitis C patients.

“when we proactively screened less than 500 individuals at top risk, among them, we found 38 additional HCV patients.”

NEJM AI Grand Rounds · 0:00:03

Ran Balicer says Clalit tests about 50,000 previously untested people for hepatitis C each year under international recommendations, finding around 38 cases.

“So every year, Clalete follows the international recommendations and tests 50 ,000 previously untested people.”

NEJM AI Grand Rounds · 0:47:18